The Australian Synchrotron
The ACRF Detector enables the shape and function of proteins to be analysed on the Australian Synchrotron’s Micro Crystallography (MX2) beamline in a fraction of the time it took previously, providing a ten-fold increase in capacity crucial to accelerating cancer drug development.
ACRF’s investment in this key cancer research technology, available at only a handful of other synchrotron facilities around the world, will lead to better outcomes for people living with cancer.
By increasing the capacity for drug development research in Australia, it is Australians with cancer who will be the first to benefit as novel treatments move from laboratories into clinical trials at our public hospitals.
The ACRF Detector at the Australian Synchrotron was officially opened in March 2017.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.